Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Bristol-Myers Squibb Company rose 39 cents (1.1%) to $34.85 on average volume. Throughout the day, 9.1 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.9 million shares. The stock ranged in a price between $34.32-$34.86 after having opened the day at $34.37 as compared to the previous trading day's close of $34.46. Other companies within the Health Care sector that increased today were: Aoxing Pharmaceutical Company ( AXN), up 21.7%, Oxygen Biotherapeutics ( OXBT), up 18.5%, Keryx Biopharmaceuticals ( KERX), up 15.9%, and Galectin Therapeutics ( GALT), up 13.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $56.88 billion and is part of the drugs industry. The company has a P/E ratio of 30.9, above the S&P 500 P/E ratio of 17.7. Shares are up 5.7% year to date as of the close of trading on Friday. Currently there are seven analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Arena Pharmaceuticals ( ARNA), down 9.7%, Uroplasty ( UPI), down 8.1%, ERBA Diagnostics ( ERB), down 7.7%, and Albany Molecular Research ( AMRI), down 7.2%, were all laggards within the health care sector with Edwards Life ( EW) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact